Recently, Azuma et al. evaluated PD-L1 expression level by immunohistochemistry in surgically resected NSCLC samples; they confirmed that PD-L1 overexpression correlated with activating EGFR mutations [62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.